Ridgetech Inc

RDGTHealthcare·Pharmaceutical Retailers·China·Nano·NASD·Nov 11 • 3:59 PM ET

1.16+0.05 (4.50%)

2026-11-12 05:46 CET

Market cap

4.21 USD m

Revenue, TTM

132.16 USD m

Net income, TTM

-1.25 USD m

Free cash flow, TTM

-1.39 USD m

EPS diluted, TTM

-2.88

P/E

Compare

Price

RDGT against its 20, 50 and 200-day averages

2050200

99.8% under the 52-week high of 760.50 on 19 Nov 2025. 52-week low 0.67 on 5 Aug 2026. Last 15 sessions, 66.0% high to low

Volume 0.15× normal · the line is the 50-bar volume average

Profile

RDGT

52-week range, 0% of the way up

0.67760.5

Ridgetech, Inc. engages in retailing and distributing pharmaceutical and other healthcare products. It operates through the following business segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. The Retail Drugstores segment refers to the selling of prescription and over-the-counter medicines, dietary supplements, medical devices, and sundry items to retail customers. The Online Pharmacy segment is involved in selling of over-the-counter drugs, dietary supplements, medical devices, and sundry items through several third-party platforms. The Drug Wholesale segment includes supplying its retail drugstores with prescription and over-the-counter medicines, and selling its products to other drug vendors and hospitals. The Herb Farming cultivates selected herbs for sales to other drug vendors. The company was founded by Li Qi in September 2003 and is headquartered in Hangzhou, China.

Employees	64
IPO	May 16, 2008
Beta	-0.27
ATR, 14d	0.10
Rel volume	0.15
Short float	4.89%
Insider own	0.41%
Inst own	4.13%

Snapshot

6 groups

Valuation

Index	-
Market Cap	4.21M
Enterprise Value	-13.68M
Income	-1.25M
Sales	132.16M
Book/sh	45.96
Cash/sh	4.93
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	64
IPO	May 16, 2008

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	0.03
P/B	0.03
P/C	0.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.10
Quick Ratio	2.01
Current Ratio	2.31
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

Earnings

EPS (ttm)	-2.88
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	85.96% 70.07%
Sales past 3/5Y	-3.88% -0.15%
EPS Y/Y TTM	98.05%
Sales Y/Y TTM	10.16%
EPS Q/Q	96.35%
Sales Q/Q	17.70%
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	0.41%
Insider Trans	183.05%
Inst Own	4.13%
Inst Trans	1.72%
ROA	-1.87%
ROE	-3.55%
ROIC	-3.07%
Gross Margin	3.60%
Oper. Margin	-1.41%
Profit Margin	-0.95%
SMA20	32.35%
SMA50	31.65%
SMA200	-97.85%
Trades	-

Technical

Shs Outstand	3.63M
Shs Float	3.61M
Short Float	4.89%
Short Ratio	0.49
Short Interest	0.18M
52W High	760.50 -99.85%
52W Low	0.67 73.13%
Volatility	18.14% 9.45%
ATR (14)	0.10
RSI (14)	68.91
Beta	-0.27
Rel Volume	0.15
Avg Volume	357.15K
Volume	54,495

Performance

Perf Week	48.72%
Perf Month	34.90%
Perf Quarter	32.12%
Perf Half Y	-18.31%
Perf YTD	-99.73%
Perf Year	-99.79%
Perf 3Y	-99.83%
Perf 5Y	-99.99%
Perf 10Y	-100.00%
Recom	-
Target Price	-
Prev Close	1.11
Price	1.16
Change %	4.50%

Peers

Mkt cap

Ticker	Company	Mkt cap
POM	Pomdoctor Ltd	13.84M
YI	111 Inc ADR	15.21M
HKPD	Cellyan Biotechnology Co Ltd	4.02M
UPC	Universe Pharmaceuticals INC	7.89M
MEDS	DataMEDS AI Inc	4.29M
MCK	Mckesson Corp	124.67B
COSM	Cosmos Health Inc	23.77M
CPHI	China Pharma Holdings Inc	23.37M
SXTC	China SXT Pharmaceuticals Inc	1.95M
AHG	Akso Health Group ADR	1.15B

Ticker

Company

Mkt cap

POM

Pomdoctor Ltd

13.84M

111 Inc ADR

15.21M

HKPD

Cellyan Biotechnology Co Ltd

4.02M

UPC

Universe Pharmaceuticals INC

7.89M

MEDS

DataMEDS AI Inc

4.29M

MCK

Mckesson Corp

124.67B

COSM

Cosmos Health Inc

23.77M

CPHI

China Pharma Holdings Inc

23.37M

SXTC

China SXT Pharmaceuticals Inc

1.95M

AHG

Akso Health Group ADR

1.15B

Insider trading

8 filings

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
HRT FINANCIAL LP	10% Owner	Jun 30 '26	Buy	1.52	30,939	47,027	90,302	Jul 02 02:01 PM
HRT FINANCIAL LP	10% Owner	Jul 01 '26	Buy	1.50	10,197	15,296	100,499	Jul 02 02:01 PM
HRT FINANCIAL LP	10% Owner	Jun 16 '26	Sale	1.60	57,998	92,855	61,753	Jun 18 05:22 PM
HRT FINANCIAL LP	10% Owner	Jun 15 '26	Sale	1.60	8,091	12,946	119,751	Jun 17 04:28 PM
HRT FINANCIAL LP	10% Owner	Jun 12 '26	Sale	1.51	6,526	9,854	127,842	Jun 16 09:46 AM
HRT FINANCIAL LP	10% Owner	Jun 11 '26	Buy	1.61	19,373	31,152	134,368	Jun 12 03:39 PM
HRT FINANCIAL LP	10% Owner	Jun 09 '26	Buy	1.78	25,024	44,568	100,683	Jun 11 03:51 PM
HRT FINANCIAL LP	10% Owner	Jun 10 '26	Buy	1.62	14,312	23,143	114,995	Jun 11 03:51 PM

News

latest 14 of 200

Jul-31-26 08:30AMRidgetech, Inc. Reports Fiscal Year 2026 Financial Results (PR Newswire)
Jul-24-26 08:30AMRidgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association (PR Newswire) -10.07%
Apr-07-26 10:30AMBC-Most Active Stocks (Associated Press) +47.54%
Apr-06-26 10:30AMBC-Most Active Stocks (Associated Press) -25.61%
Apr-03-26 12:00PMRidgetech, Inc. Announces 1-for-150 Reverse Share Split (PR Newswire)
Apr-02-26 10:30AMBC-Most Active Stocks (Associated Press) -11.51%
Apr-01-26 10:30AMBC-Most Active Stocks (Associated Press) -14.72%
Mar-31-26 10:30AMBC-Most Active Stocks (Associated Press) +5.50%
Mar-30-26 10:30AMBC-Most Active Stocks (Associated Press) -29.29%
Mar-04-26 08:30AMRidgetech Unveils 2026 Dual-Engine Growth Strategy to Drive Innovation and Value Creation (PR Newswire)
Jul-28-25 09:00AMRidgetech, Inc. Reports Fiscal Year 2025 Financial Results (PR Newswire)
Feb-03-25 08:00AMChina Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth (PR Newswire) -11.95%
Jul-30-24 09:00AMChina Jo-Jo Drugstores Reports Fiscal Year 2024 Financial Results (PR Newswire)
Jun-11-24 09:00AMChina Jo-Jo Drugstores Announces $3.37 Million Registered Direct Offering (PR Newswire) -10.04%

Key figures

Revenue, TTM	132.16
Net income, TTM	-1.25
EPS diluted, TTM	-2.88
EBIT, TTM	-1.87
Free cash flow, TTM	-1.39
Gross margin	3.60%
Operating margin	-1.41%
Net margin	-0.95%
Market cap	4.21
P/E	-
Sales Y/Y, TTM	10.16%

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
No quarterly earnings.

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

No quarterly earnings.

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
2012FY	-58,479	-	-38,160	89.50	-

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

2012FY

-58,479

-38,160

89.50

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS, annual	-24479.998	-1152.36	-6377.399	-7167.959	-33028.557	-6219.327	-439.764	-150.546	-17.208
EPS, quarterly
Period
Sales, annual	96.113	107.551	117.328	133.135	164.393	148.812	123.994	119.972	132.164
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025
Sales, quarterly
Period
Shares, annual	0.001	0.001	0.001	0.001	0	0.008	0.012	0.039	0.887
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Total Revenue	132.16	132.16	119.97	123.99	148.81	164.39	133.13	117.33	107.55
Cost of Goods Sold Incl. D&A	127.41	127.41	116.13	119.12	114.53	127.87	103.89	91.80	82.44
Gross Profit	4.75	4.75	3.84	4.88	34.28	36.52	29.24	25.53	25.11
Selling, General and Administrative Excl. Other	6.62	6.62	4.87	4.28	55.21	39.06	37.85	31.90	25.98
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-1.87	-1.87	-1.04	0.60	-20.93	-2.55	-8.61	-6.38	-0.88
Interest Expense	-	0.07	-	0.01	0.07	0.26	0.46	0.70	-
Unusual Expense	0.00	0.00	0.00	0.00	0.00	0.15	0.16	0.23	0.33
Net Income Before Taxes	-1.35	-1.35	-0.95	-0.83	-20.74	-2.10	-8.34	-6.44	-1.18
Income Taxes	-0.10	-0.10	0.50	-0.04	0.39	1.10	0.03	0.02	0.13
Consolidated Net Income	-1.25	-1.25	-1.45	-0.79	-21.14	-3.20	-8.38	-6.46	-1.32
Net Income From Continuing Operations	-1.25	-1.25	-1.46	-0.79	-21.14	-3.19	-8.12	-5.81	-0.93
Net Income	-1.25	-1.25	-5.56	-4.23	-21.14	-3.19	-8.12	-5.81	-0.93
EPS (Recurring)	-1.41	-17.21	-150.55	-439.76	-6,219.31	-31,950.72	-7,066.36	-6,202.96	-868.08
EPS (Basic, Before Extraordinaries)	-2.88	-17.21	-150.55	-439.76	-6,219.33	-33,028.56	-7,167.96	-6,377.40	-1,152.36
EPS (Diluted)	-2.88	-17.21	-150.55	-439.76	-6,219.33	-33,028.56	-7,167.96	-6,377.40	-1,152.36
EBITDA	-1.50	-1.50	3.90	5.25	-20.21	-1.29	-6.80	-4.29	0.57
Non-Operating Income (Expense)	0.58	0.58	0.08	-1.42	0.25	0.86	0.88	0.86	0.02
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	-	-	0.00	0.00	8.18	0.00	2.96	0.03	0.15
Price To Sales Ratio	0.03	0.00	0.05	0.04	0.31	0.01	0.34	0.51	0.70
Gross Margin	3.60	3.60	3.20	3.93	23.04	22.21	21.97	21.76	23.35
Operating Margin	-1.41	-1.41	-0.86	0.48	-14.06	-1.55	-6.47	-5.43	-0.81
Net Margin	-0.95	-0.95	-4.64	-3.41	-14.20	-1.94	-6.10	-4.95	-0.86
Shares Outstanding	0.89	0.89	0.04	0.01	0.01	0.00	0.00	0.00	0.00
Market Capitalization	4.21	4.21	6.15	5.30	106.16	1.10	46.76	59.62	75.81

Income statement, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1	2022S2	2022S1
Total Revenue	69.36	62.81	48.81	71.16	75.97	78.57	76.09	72.72
Cost of Goods Sold Incl. D&A	67.07	60.34	47.62	56.56	60.79	62.64	58.73	55.80
Gross Profit	2.29	2.46	1.19	14.60	15.18	15.93	17.36	16.92
Selling, General and Administrative Excl. Other	4.08	2.54	-	16.82	18.97	15.68	37.04	18.17
Other Operating Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-1.79	-0.07	1.19	-2.22	-3.79	0.26	-19.68	-1.24
Interest Expense	0.07	-	-	0.00	0.01	0.00	0.01	0.06
Unusual Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income Before Taxes	-1.30	-0.05	1.32	-2.27	-3.29	-0.89	-20.59	-0.16
Income Taxes	-0.11	0.01	0.49	0.01	0.02	0.04	-0.04	0.44
Consolidated Net Income	-1.19	-0.06	0.82	-2.28	-3.31	-0.92	-20.54	-0.60
Net Income From Continuing Operations	-1.19	-0.06	0.82	-2.28	-3.31	-0.92	-20.54	-0.59
Net Income	-1.19	-0.06	-3.29	-2.28	-3.31	-0.92	-20.54	-0.59
EPS (Recurring)	-1.34	-1.54	-84.19	-63.51	-284.79	-115.94	-5,825.77	-393.54
EPS (Basic, Before Extraordinaries)	-1.34	-1.54	-84.19	-63.51	-284.79	-115.95	-5,825.76	-393.54
EPS (Diluted)	-1.34	-1.54	-84.19	-63.51	-284.79	-115.95	-5,825.76	-393.54
EBITDA	-1.58	0.08	2.31	1.60	1.27	0.58	-19.59	-0.61
Non-Operating Income (Expense)	0.56	0.02	0.13	-0.04	0.52	-1.14	-0.90	1.15
Stock Option Compensation Expense	-	-	-	-	-	-	8.18	-
Price To Sales Ratio	0.03	0.06	0.05	0.08	0.04	0.04	0.32	0.06
Gross Margin	3.30	3.92	2.43	20.51	19.98	20.28	22.81	23.27
Operating Margin	-2.58	-0.12	2.43	-3.12	-4.99	0.33	-25.87	-1.71
Net Margin	-1.72	-0.10	-6.73	-3.20	-4.36	-1.18	-27.00	-0.82
Shares Outstanding	0.89	0.04	0.04	0.04	0.01	0.01	0.01	0.00
Market Capitalization	4.21	7.25	6.15	14.84	5.30	5.52	106.16	10.46

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY	2017FY
Cash & Short Term Investments	17.91	18.54	4.29	31.57	35.43	34.76	31.14	24.93	31.63
Short Term Receivables	37.99	30.23	6.25	16.84	22.50	18.52	14.90	13.31	11.70
Inventories	8.36	10.19	9.26	15.45	16.59	17.39	13.42	15.91	16.88
Other Current Assets	0.29	0.75	49.88	0.62	0.92	1.56	1.53	2.06	2.12
Total Current Assets	64.56	59.71	69.68	64.48	75.45	72.23	60.99	56.20	62.32
Net Property, Plant & Equipment	0.01	0.01	0.01	19.69	20.38	24.16	30.09	9.55	3.64
Total Investments and Advances	0.00	0.00	0.00	1.77	4.42	3.98	2.54	0.02	0.04
Intangible Assets	4.47	4.77	1.28	3.20	3.55	3.53	3.39	3.60	4.06
Other Assets	0.00	0.00	24.09	1.83	2.58	2.40	2.50	3.35	3.76
Total Assets	69.03	64.48	95.06	90.97	106.38	106.31	99.52	72.73	73.81
Short Term Debt Incl. Current Port. of LT Debt	0.02	10.39	6.59	34.39	39.48	29.77	31.28	25.95	19.18
Accounts Payable	22.76	19.67	30.58	26.99	27.33	29.90	21.56	23.11	25.26
Income Tax Payable	1.79	1.52	0.54	1.71	1.38	0.20	0.12	0.13	0.37
Other Current Liabilities	3.32	2.78	36.65	3.45	6.26	5.03	4.47	6.03	10.01
Total Current Liabilities	27.89	34.36	74.36	66.54	74.45	64.90	57.44	55.21	54.81
Long Term Debt	0.00	0.00	0.00	7.77	9.20	17.01	23.17	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liabilities	0.36	0.49	-	-	-	-	-	-	-
Other Liabilities	0.00	0.00	6.40	0.00	0.00	0.00	0.13	0.55	0.14
Total Liabilities	28.25	34.85	80.76	74.30	83.65	81.91	80.74	55.76	54.95
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	40.78	29.64	15.64	18.01	24.09	25.74	20.59	18.17	18.86
Total Shareholders Equity	40.78	29.64	15.64	18.01	24.09	25.74	20.59	18.17	18.86
Accumulated Minority Interest	0.00	0.00	-1.35	-1.35	-1.35	-1.34	-1.81	-1.19	0.00
Total Equity	40.78	29.64	14.29	16.67	22.74	24.40	18.78	16.97	18.86
Total Liabilities & Stockholders Equity	69.03	64.48	95.06	90.97	106.38	106.31	99.52	72.73	73.81
Book Value Per Share	45.96	759.26	1,345.68	2,280.52	249,208.20	22,196.35	22,505.95	22,599.18	23,466.56
Tangible Book Value Per Share	40.93	637.14	1,235.82	1,875.95	212,497.67	19,154.32	18,796.34	18,123.78	18,420.01
Full-Time Employees	64	61	1,003	938	979	1,047	1,074	1,079	1,139
Price to Book Ratio	0.03	0.21	0.28	5.89	0.05	1.82	2.90	5.36	1.35
Return on Assets	-1.87	-1.83	-0.84	-21.42	-3.00	-7.89	-6.75	-1.26	-24.20
Return on Equity	-3.55	-6.45	-4.67	-100.42	-12.81	-35.05	-30.00	-5.00	-74.94
Return on Invested Capital	-3.07	-18.77	-27.07	-81.99	-9.59	-18.99	-13.29	-5.10	-90.44
Quick Ratio	2.01	1.44	0.81	0.74	0.79	0.85	0.83	0.73	0.83
Current Ratio	2.31	1.74	0.94	0.97	1.01	1.11	1.06	1.02	1.14

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Net Income	-1.25	-1.25	10.20	-4.23	-21.14	-3.20	-8.38	-6.46	-1.32
Depreciation	0.36	0.36	6.02	5.38	0.72	1.26	1.75	2.08	1.45
Other Funds (Non Cash)	-0.43	-0.43	-15.67	1.47	20.26	1.09	3.40	0.71	-2.61
Funds from Operations	-1.39	-1.39	0.51	2.62	-0.16	-0.85	-3.23	-3.67	-2.48
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	0.00	0.00	0.73	-5.77	-3.12	-4.53	3.16	-3.24	-3.13
Income Taxes Payable	0.18	0.18	1.31	-0.95	0.43	1.16	0.07	0.00	-0.22
Cash from Operating Activities	-1.39	-1.39	1.25	-3.16	-3.28	-5.39	-0.06	-6.91	-5.60
Capital Expenditures	-0.00	-0.00	-0.62	-0.92	-0.31	-0.31	-0.60	-1.53	-5.48
Net Assets From Acquisitions	0.00	0.00	-22.35	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	4.83	0.00	0.00	0.00	0.00	0.00	-
Purchase or Sale of Investments	0.00	0.00	0.00	-1.12	-0.00	0.00	-1.39	-2.55	-0.02
Purchase of Investments	0.00	0.00	0.00	-1.12	-0.00	0.00	-1.47	-2.57	-0.10
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.01	0.09
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.76	-1.83
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Cash from Investing Activities	-0.00	-0.00	-18.14	-2.04	-0.32	-0.31	-2.00	-4.84	-7.33
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	10.88	10.88	7.63	2.59	7.33	0.00	9.36	9.27	0.01
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	10.88	10.88	7.63	2.59	7.33	0.00	9.36	9.27	0.01
Proceedsfrom Stock Options	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	-10.91	-10.91	-6.45	4.16	-4.12	4.15	-6.14	10.03	8.01
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.33	1.26	-0.84	0.69	-0.15	-0.29	0.06
Other Financing Activities Uses	0.00	0.00	-	0.00	-0.88	0.00	-0.15	-0.29	-0.02
Cash from Financing Activities	-0.03	-0.03	1.51	8.00	2.37	4.84	3.08	19.01	8.08
Exchange Rate Effect	0.80	0.80	1.05	-1.51	-2.54	1.52	2.67	-1.03	-1.86
Net Change in Cash	-0.63	-0.63	-14.33	1.30	-3.77	0.67	3.69	6.24	-6.71
Free Cash Flow	-1.39	-1.39	1.09	-3.49	-3.40	-5.48	-0.19	-7.56	-11.05
Preferred Dividends (Cash Flow)	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Free Cash Flow	-	-	5.33	-	-	-	-	-	-
Deferred Taxes & Investment Tax Credit	-	-0.08	-0.03	0.00	0.00	0.00	0.00	0.00	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1
Cash & Short Term Investments	17.91	18.05	18.54	31.09	32.87	29.60
Short Term Receivables	37.99	28.18	30.23	19.38	19.08	19.66
Inventories	8.36	10.51	10.19	19.84	17.16	20.04
Other Current Assets	0.29	0.00	0.75	0.77	0.57	0.52
Total Current Assets	64.56	56.74	59.71	71.08	69.68	69.82
Net Property, Plant & Equipment	0.01	0.01	0.01	17.09	19.37	18.98
Total Investments and Advances	0.00	0.00	0.00	1.23	1.20	1.16
Intangible Assets	4.47	4.64	4.77	3.06	3.01	2.99
Other Assets	0.00	0.00	0.00	1.74	1.80	1.81
Total Assets	69.03	61.39	64.48	94.19	95.06	94.77
Short Term Debt Incl. Current Port. of LT Debt	0.02	4.66	10.39	35.63	36.82	29.57
Accounts Payable	22.76	21.85	19.67	27.24	31.63	34.40
Income Tax Payable	1.79	1.56	1.52	0.51	0.68	1.66
Other Current Liabilities	3.32	3.05	2.78	4.15	5.23	4.16
Total Current Liabilities	27.89	31.12	34.36	67.54	74.36	69.78
Long Term Debt	0.00	0.00	0.00	6.53	6.40	7.45
Deferred Tax Liabilities	0.36	0.48	0.49	-	-	-
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	28.25	31.61	34.85	74.07	80.76	77.23
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	40.78	29.78	29.64	21.47	15.64	18.88
Total Shareholders Equity	40.78	29.78	29.64	21.47	15.64	18.88
Accumulated Minority Interest	0.00	0.00	0.00	-1.35	-1.35	-1.35
Total Equity	40.78	29.78	29.64	20.12	14.29	17.54
Total Liabilities & Stockholders Equity	69.03	61.39	64.48	94.19	95.06	94.77
Book Value Per Share	45.96	762.93	759.26	483.94	1,345.68	1,683.28
Tangible Book Value Per Share	40.93	644.04	637.14	415.03	1,086.70	1,416.70
Price to Book Ratio	0.03	0.24	0.21	0.69	0.28	0.31
Return on Assets	-1.87	0.97	-1.83	-5.91	-4.55	-21.85
Return on Equity	-3.55	2.96	-6.45	-27.69	-25.16	-101.83
Return on Invested Capital	-2.92	-0.20	-11.09	-8.13	-15.02	-3.51
Quick Ratio	2.01	1.49	1.44	0.76	0.71	0.71
Current Ratio	2.31	1.82	1.74	1.05	0.94	1.00

Cash flow, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1
Net Income	-1.19	-0.06	12.48	-2.28	-3.31	-0.92
Depreciation	0.21	0.15	2.20	3.82	5.06	0.32
Other Funds (Non Cash)	-0.57	0.14	-15.47	-0.20	0.71	0.75
Funds from Operations	-1.63	0.23	-0.82	1.34	2.47	0.15
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-5.11	5.11	12.03	-11.29	-6.34	0.57
Income Taxes Payable	0.17	0.01	1.50	-0.19	-1.00	0.05
Cash from Operating Activities	-6.74	5.35	11.20	-9.95	-3.88	0.72
Capital Expenditures	-0.00	0.00	-0.18	-0.43	-0.72	-0.20
Net Assets From Acquisitions	0.00	0.00	-22.35	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	4.83	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.01	-1.12
Purchase of Investments	0.00	0.00	0.00	0.00	0.01	-1.12
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.00	0.00
Cash from Investing Activities	-0.00	0.00	-17.70	-0.43	-0.71	-1.33
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	10.88	0.00	0.00	7.63	0.00	2.59
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	10.88	0.00	0.00	7.63	0.00	2.59
Proceedsfrom Stock Options	0.00	0.00	0.00	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	-5.05	-5.87	-6.55	0.10	7.24	-3.09
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.23	0.10	0.43	0.82
Other Financing Activities Uses	0.00	0.00	-	-	-	-
Cash from Financing Activities	5.84	-5.87	-6.32	7.83	7.68	0.33
Exchange Rate Effect	0.77	0.02	0.27	0.78	0.19	-1.70
Net Change in Cash	-0.13	-0.50	-12.55	-1.78	3.27	-1.97
Free Cash Flow	-6.74	5.35	11.20	-10.11	-4.20	0.71
Price to Free Cash Flow	-	0.44	5.63	-	-	-

Revenue breakdown

Revenue From Offline Wholesale	2024: 118.86M 2025: 117.87M
Revenue From Online Platform	2024: 1.11M 2025: 14.29M
China	2024: 119.97M 2025: 132.16M

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	4.89%	0.2M	3.6M	1.49M
2026-10-15	4.63%	0.2M	3.6M	2.03M
2026-09-30	7.18%	0.3M	3.6M	2.30M
2026-09-15	6.56%	0.2M	3.6M	3.81M
2026-08-31	9.87%	0.4M	3.6M	4.17M
2026-08-14	8.64%	0.3M	3.6M	4.15M
2026-07-31	5.23%	0.1M	1.4M	2.94M
2026-07-15	-	0.0M	-	2.44M
2026-06-30	3.76%	0.0M	0.9M	2.47M
2026-06-15	9.71%	0.1M	0.9M	897.90K
2026-05-29	1.86%	0.0M	0.9M	495.38K
2026-05-15	1.39%	0.0M	0.9M	470.86K
2026-04-30	6.52%	0.1M	0.8M	453.85K
2026-04-15	15.57%	0.1M	0.8M	423.94K
2026-03-31	0.02%	0.0M	16.0M	112.60K
2026-03-13	0.09%	0.0M	0.1M	78
2026-02-27	0.07%	0.0M	0.1M	65
2026-02-13	0.08%	0.0M	0.1M	213
2026-01-30	0.08%	0.0M	0.1M	796
2026-01-15	0.17%	0.0M	0.1M	806

Option chain

expiry 2026-11-11

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-06	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-11-06	SEC
2026-09-09	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-09-09	SEC
2026-09-01	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-09-01	SEC
2026-08-28	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-08-28	SEC
2026-08-05	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-08-05	SEC
2026-07-31	20-F	Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.	2026-03-31	SEC
2026-07-31	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-31	SEC
2026-07-29	424B5			SEC
2026-07-28	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-28	SEC
2026-07-21	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-21	SEC
2026-07-20	SCHEDULE 13D/A			SEC
2026-07-20	4	Statement of changes in beneficial ownership of securities	2026-07-16	SEC
2026-07-20	3	Initial statement of beneficial ownership of securities	2026-03-18	SEC
2026-07-20	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-20	SEC
2026-07-02	4	Statement of changes in beneficial ownership of securities	2026-06-30	SEC
2026-07-02	3	Initial statement of beneficial ownership of securities	2026-06-30	SEC
2026-06-18	4	Statement of changes in beneficial ownership of securities	2026-06-09	SEC
2026-06-17	4	Statement of changes in beneficial ownership of securities	2026-06-09	SEC
2026-06-16	4	Statement of changes in beneficial ownership of securities	2026-06-09	SEC
2026-06-12	4	Statement of changes in beneficial ownership of securities	2026-06-09	SEC
2026-06-11	4	Statement of changes in beneficial ownership of securities	2026-06-09	SEC
2026-06-11	3	Initial statement of beneficial ownership of securities	2026-06-09	SEC
2026-04-10	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-04-10	SEC
2026-04-03	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-04-03	SEC
2026-03-05	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-09-30	SEC
2025-12-30	424B5			SEC
2025-12-30	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-12-30	SEC
2025-12-16	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-12-16	SEC
2025-12-15	EFFECT	Effectiveness filing by commission order		SEC
2025-12-12	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-12-12	SEC

Insider activity by month

Month	Bought	Buys	Sold	Sells
2026-11	0	0	0	0
2026-10	0	0	0	0
2026-09	0	0	0	0
2026-08	0	0	0	0
2026-07	15.30K	1	0	0
2026-06	145.89K	4	115.65K	3
2026-05	0	0	0	0
2026-04	0	0	0	0
2026-03	0	0	0	0
2026-02	0	0	0	0
2026-01	0	0	0	0
2025-12	0	0	0	0
2025-11	0	0	0	0

Institutional holders

Manager	% owned
HRT FINANCIAL LP	10.05%
Virtu Financial LLC	3.20%
StoneX Group Inc.	0.29%
UBS Group AG	0.27%
HHLR ADVISORS, LTD.	0.02%
HARBOUR INVESTMENTS, INC.	0.00%

Funds

Fund	% owned
-

Fund

% owned

OakChart. RDGT. Cached 15 minutes.

Some panels did not load: ratings.